TICKERNERD
Menu
INCYINCYHealthcare · Biotechnology

INCY Stock Forecast: Incyte Corp. Price Predictions for 2026-2027

Last close, 17 Aug 2026
$124
+2.78% on the day

The 27 Wall Street analysts covering Incyte Corp. hold a median 12-month price target of $120 — -2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 17 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$24.4B
Ticker Nerd rank
90 / 100
Median analyst target
$120
Analysts covering
27
Total return, dividends reinvested
1W
+1.6%
1M
+5.3%
YTD
+25.0%
1Y
+42.1%
From 52W high
−4.9%
From 52W low
+51.2%
$82
$130
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INCY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Incyte Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
98
Quality
97
Momentum
87
Growth
86
Issuance
72
Revisions
46
Accruals
46
Size
9

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (46): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INCY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INCY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26INCYHigh $155Median $120Low $86

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says27 analysts
11 Buy15 Hold1 Sell
Low $86Median $120High $155

The green dot is the last close — the median target sits −2.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Aug 2026MizuhoMaintainsOutperform$121 → $137
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$150
3 Aug 2026Leerink PartnersMaintainsOutperform$131 → $155
29 July 2026BarclaysMaintainsOverweight$134 → $139
29 July 2026BMO CapitalMaintainsMarket Perform$112 → $130
29 July 2026GuggenheimMaintainsBuy$136 → $150
29 July 2026HC Wainwright & Co.MaintainsBuy$140 → $150
29 July 2026RBC CapitalMaintainsSector Perform$99 → $109
23 July 2026JP MorganMaintainsNeutral$105 → $110
23 July 2026JP MorganMaintainsNeutral—
23 July 2026Morgan StanleyMaintainsEqual-Weight—
23 July 2026Morgan StanleyMaintainsEqual-Weight$103 → $104
21 July 2026HC Wainwright & Co.ReiteratesBuy$140
21 July 2026HC Wainwright & Co.ReiteratesBuy—
14 July 2026BarclaysMaintainsOverweight—
14 July 2026BarclaysMaintainsOverweight$117 → $134
13 July 2026BMO CapitalMaintainsMarket Perform$94 → $112
13 July 2026BMO CapitalMaintainsMarket Perform—
7 July 2026RBC CapitalMaintainsSector Perform—
7 July 2026RBC CapitalMaintainsSector Perform$95 → $99

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INCY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

INCY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−53.9%
Analysts raising
0
Analysts cutting
11
Fundamentals

Incyte Corp. (INCY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.3×

Cheaper than 47% of US stocks

Price / sales
4.2×

Cheaper than 31% of US stocks

Price / book
3.8×

Cheaper than 29% of US stocks

EV / EBITDA
10.2×

Cheaper than 38% of US stocks

Growth & margins
Revenue growth (YoY)
37.7%

Higher than 82% of US stocks

Earnings growth (YoY)
44.6%

Higher than 73% of US stocks

Gross margin
93.7%

Higher than 98% of US stocks

Operating margin
41.9%

Higher than 93% of US stocks

Net margin
27.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
30.7%

Higher than 88% of US stocks

Return on assets
16.8%

Higher than 98% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INCY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INCYIncyte Corp.$24.4B
90
MRNAModerna, Inc.$25.7B
76
ROIVRoivant Sciences Ltd.$25.9B
35
INSMInsmed, Inc.$28.0B
86
ALNYAlnylam Pharmaceuticals, Inc.$29.7B
55
RPRXRoyalty Pharma plc$34.2B
87
JAZZJazz Pharmaceuticals Plc$15.6B
100

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Incyte Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INCY news & analysis

Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness

Business Wire · 17 Aug 2026positive

The Global Vitiligo Foundation publicly recognised and supports Incyte's Moments of Clarity campaign, a storytelling initiative that shares the lived experiences of people with nonsegmental vitiligo. GVF said the campaign aligns with its mission to improve quality of life for those affected by the condition through education, advocacy and community connection.

Why it matters — Endorsement from a leading patient-advocacy organisation highlights the reach and credibility of Incyte's vitiligo-focused patient-engagement efforts.

Incyte Sales Growth Drives Share Price Gains

FXEmpire · 12 Aug 2026positive

Incyte Corporation has received backing from large institutional investors, and its share price has risen 23% so far in 2026. The gains are attributed to sales growth.

Why it matters — A strong 23% share-price gain driven by sales growth indicates improving commercial performance for Incyte in 2026.

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 7 Aug 2026neutral

Incyte Corp. announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The release, issued via Business Wire from Wilmington, Delaware, reports equity awards made as an inducement for new employees.

Why it matters — Incyte watchers would care because this is a routine disclosure of equity compensation grants tied to hiring, which affects share counts and compensation practices.

REGN or INCY: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 5 Aug 2026neutral

Zacks Investment Research compares Regeneron (REGN) and Incyte (INCY) as potential value-stock picks within the Medical - Biomedical and Genetics sector, evaluating which of the two is more attractive to value investors.

Why it matters — INCY watchers would care because the article directly assesses Incyte's appeal as a value investment relative to a sector peer.

Here's Why Incyte (INCY) is a Strong Momentum Stock

Zacks Investment Research · 30 July 2026positive

Zacks Investment Research highlighted Incyte (INCY) as a strong momentum stock through its Style Scores system, which helps investors identify top-rated stocks based on investing style.

Why it matters — INCY watchers would care because a strong momentum designation from Zacks could attract attention from momentum-focused investors, potentially influencing near-term trading activity in the stock.

FAQ

Frequently asked questions about INCY stock

What is the INCY stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Incyte Corp. have a median 12-month price target of $120, with estimates ranging from $86 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INCY stock a buy right now?

Of the 27 analysts covering Incyte Corp., 11 rate it a Buy, 15 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Incyte Corp. 90 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INCY?

As at 17 Aug 2026, Incyte Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will INCY stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies -2.8% from the last close, and Ticker Nerd's factor model ranks Incyte Corp. 90 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INCY stock forecast for 2030?

No analyst covering Incyte Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $155 over the next 12 months.

How has INCY stock performed over the past year?

Incyte Corp. returned +42.1% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Incyte Corp. do?

Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates on hematology and oncology, as well as inflammation, autoimmunity, and dermatology, addressing diseases with significant unmet medical needs.

What is the latest news on INCY?

The most recent item we track (Business Wire, 17 Aug 2026): "Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness". The Global Vitiligo Foundation publicly recognised and supports Incyte's Moments of Clarity campaign, a storytelling initiative that shares the lived experiences of people with nonsegmental vitiligo. GVF said the campaign aligns with its mission to improve quality of life for those affected by the condition through education, advocacy and community connection.

Company

About Incyte Corp.

Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates on hematology and oncology, as well as inflammation, autoimmunity, and dermatology, addressing diseases with significant unmet medical needs. A core part of its business is small-molecule drug development, supported by a broad pipeline of oncology and dermatology programs. Incyte’s portfolio includes Jakafi for certain rare blood cancers and graft-versus-host disease, along with partnered and licensed therapies such as Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. The company also markets Opzelura, a topical treatment for atopic dermatitis and vitiligo in dermatology. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte plays a notable role in the healthcare and biotechnology sectors by providing targeted therapies that are integrated into specialized care across global markets.

CEO Mr. William J. Meury · 2,844 employees · United States · https://www.incyte.com